Results from San Antonio Breast Cancer Symposium

This is the big one, ladies. This is where you will hear about the new, the best, the better in addition to what isn’t working.

You may want to browse their website:

Physicians, researchers and advocates from all around the world came away from the 2009 SABCS with answers to a number of important questions: Is beginning on an aromatase inhibitor better than switching from tamoxifen? Is Herceptin more effective with or following chemotherapy in HER2-positive breast cancer? Does Avastin slow progression of metastatic breast cancer and by how much? And how well does Xgeva work against bone pain and fracture when compared with Zometa? Get an update on last year’s breaking news

-maven

San Antonio Breast Cancer Symposium 2010 - Sign up for news!

The San Antonio Breast Cancer symposium is one of the world’s largest meetings focused specifically on breast cancer, and CURE will be covering the entire meeting every step of the way! Each day we will gather the most important breaking news, research, advocacy happenings and more and send them straight to your inbox.

By signing up for updates from San Antonio, you will be added to CURE’s breast cancer-specific e-newsletters where you will find in-depth features and articles, blogs and more!

SIGN UP TODAY!



33rd Annual San Antonio Breast Cancer Symposium

Now underway, the symposium presents a ton of great, cutting edge information about breast cancer’s breaking news, frontiers, new breakthroughs and much more.

The 2009 San Antonio Breast Cancer Symposium (SABCS) is presented by the CTRC, AACR, and the Baylor College of Medicine. The driving force behind this collaboration is the shared mission of the organizations to advance progress against breast cancer. By combining their respective strengths, the San Antonio Breast Cancer Symposium encompasses the full spectrum of breast cancer research and facilitates the rapid transition of new knowledge into improved care for breast cancer patients.

Patients are both encouraged to attend, and mine the symposium site for a multitude of resources that are constantly available. You can also view streaming video.

Hormone replacement therapy and risk

SAN ANTONIO, Dec. 16 — The elevated breast cancer risk from hormone replacement therapy quickly dissipates after combined estrogen and progestin is discontinued, researchers reported here.

Click to read more ...